Explaining the decline in coronary heart disease mortality in Portugal between 1995 and 2008

Circulation: Cardiovascular Quality and Outcomes

Volumn 6, Issue 6, 2013, Pages 634-642

  Pereira, Marta ^a,b   Azevedo, Ana ^a,b   Lunet, Nuno ^a,b   Carreira, Helena ^a,b   O'Flaherty, Martin ^c   Capewell, Simon ^c   Bennett, Kathleen ^d  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ST JAMES S HOSPITAL   (Ireland)

Author keywords

Coronary artery disease; Decision modeling; Mortality; Risk factors; Therapeutics

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HEART REHABILITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MIDDLE AGED; OBESITY; POPULATION RISK; PORTUGAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SMOKING; UNSTABLE ANGINA PECTORIS; VERY ELDERLY;

CORONARY ARTERY DISEASE; DECISION MODELING; MORTALITY; RISK FACTORS; THERAPEUTICS;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; PORTUGAL; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 84892425909     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.113.000264     Document Type: Article

References (39)

1. Levi F, Chatenoud L, Bertuccio P, Lucchini F, Negri E, La Vecchia C. Mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world: an update. Eur J Cardiovasc Prev Rehabil. 2009;16:333-350.
2. EUROCISS Working Group. Coronary and cerebrovascular population- based registers in Europe: are morbidity indicators comparable? Results from the EUROCISS Project. Eur J Public Health. 2003;13:55-60.
3. Levi F, Lucchini F, Negri E, La Vecchia C. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart. 2002;88:119-124.
4. Óbitos (N.o) por Sexo e Causa de morte. Anual [database on the Internet]. Instituto Nacional de Estatística. http://www.ine.pt/xportal/ xmain?xpid=INE&xpgid=ine-main. 2010.
5. Nichols M, Townsend N, Luengo-Fernandez R, Leal J, Gray A, Scarborough P, Rayner M. European Cardiovascular Disease Statistics 2012. Brussels: European Society of Cardiology, Sophia Antipolis; 2012.
6. Pereira M, Carreira H, Vales C, Rocha V, Azevedo A, Lunet N. Trends in hypertension prevalence (1990-2005) and mean blood pressure (1975-2005) in Portugal: a systematic review. Blood Press. 2012;21:220-226.
7. Carreira H, Pereira M, Azevedo A, Lunet N. Trends in the prevalence of smoking in Portugal: a systematic review. BMC Public Health. 2012;12:958.
8. Ferreira RJ, Marques-Vidal PM. Prevalence and determinants of obesity in children in public schools of Sintra, Portugal. Obesity (Silver Spring). 2008;16:497-500.
9. Santos JF, Aguiar C, Gavina C, Azevedo P, Morais J; Registo Nacional de Síndromes Coronárias Agudas da Sociedade Portuguesa de Cardiologia. Portuguese Registry of Acute Coronary Syndromes: seven years of activity. Rev Port Cardiol. 2009;28:1465-1500.
10. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles WH, Capewell S. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356:2388-2398.
11. Capewell S, Beaglehole R, Seddon M, McMurray J. Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. Circulation. 2000;102:1511-1516.
12. Critchley J, Liu J, Zhao D, Wei W, Capewell S. Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation. 2004;110:1236-1244.
13. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation. 2004;109:1101-1107.
14. Palmieri L, Bennett K, Giampaoli S, Capewell S. Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000. Am J Public Health. 2010;100:684-692.
15. Flores-Mateo G, Grau M, O'Flaherty M, Ramos R, Elosua R, Violan-Fors C, Quesada M, Martí R, Sala J, Marrugat J, Capewell S. Analyzing the coronary heart disease mortality decline in a Mediterranean population: Spain 1988-2005. Rev Esp Cardiol. 2011;64:988-996.
16. Correia R. Geographic and Temporal Variation of the Procedures Used in Myocardial Infarction. Porto: University of Porto, Medical School; 2011.
17. Kirchberger I, Azevedo A, Davoli M, Farmakis D, Ferrieres J, Garel P, Haekkinen U, Marrugat J, Torre M, Meisinger C. European Hospital Benchmarking in Acute Coronary Syndrome: the EURHOBOP project. Congress of the European Society of Cardiology (ESC). 2012;22:297.
18. Almeida P, Rodrigues J, Lourenço P, Maciel MJ, Bettencourt P. Prognostic significance of applying the European Society of Cardiology consensus algorithm for heart failure with preserved systolic function diagnosis. Clin Cardiol. 2012;35:770-776.
19. Pereira M, Azevedo A, Barros H. Determinants of awareness, treatment and control of hypertension in a Portuguese population. Rev Port Cardiol. 2010;29:1779-1792.
20. Gray LJ, Barros H, Raposo L, Khunti K, Davies MJ, Santos AC. The development and validation of the Portuguese risk score for detecting type 2 diabetes and impaired fasting glucose. Prim Care Diabetes. 2013;7:11-18.
21. Carreira H, Pereira M, Azevedo A, Lunet N. Trends of BMI and prevalence of overweight and obesity in Portugal (1995-2005): a systematic review. Public Health Nutr. 2012;15:972-981.
22. Carreira H, Pereira M, Alves L, Lunet N, Azevedo A. Dyslipidaemia, and mean blood cholesterol and triglycerides levels in the Portuguese population: a systematic review. Arq Med. 2012;26:112-123.
23. Instituto Nacional de Estatística. Inquérito Nacional de Saúde 1995-1996. Lisbon: Instituto Nacional de Saúde Doutor Ricardo Jorge; 1997.
24. Gardete-Correia L, Boavida JM, Raposo JF, Mesquita AC, Fona C, Carvalho R, Massano-Cardoso S. First diabetes prevalence study in Portugal: PREVADIAB study. Diabet Med. 2010;27:879-881.
25. Nichol MB, Venturini F, Sung JC. A critical evaluation of the methodology of the literature on medication compliance. Ann Pharmacother. 1999;33:531-540.
26. Butler J, Arbogast PG, BeLue R, Daugherty J, Jain MK, Ray WA, Griffin MR. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002;40:1589-1595.
27. Mant J, Hicks N. Detecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarction. BMJ. 1995;311:793-796.
28. McAlister FA. Commentary: relative treatment effects are consistent across the spectrum of underlying risks usually. Int J Epidemiol. 2002;31:76-77.
29. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994;3:95-104.
30. Aspelund T, Gudnason V, Magnusdottir BT, Andersen K, Sigurdsson G, Thorsson B, Steingrimsdottir L, Critchley J, Bennett K, O'Flaherty M, Capewell S. Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25-74 between the years 1981 and 2006. PLoS One. 2010;5:e13957.
31. Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012;366:54-63.
32. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, Farzadfar F, Stevens GA, Lim SS, Riley LM, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure). National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants. Lancet. 2011;377:568-577.
33. The INTERSALT Co-operative Research Group. Appendix tables. Centrespecific results by age and sex. J Hum Hypertens. 1989;3:331-407.
34. Macedo ME, Lima MJ, Silva AO, Alcantara P, Ramalhinho V, Carmona J. Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study. J Hypertens. 2005;23:1661-1666.
35. WHO. 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Bull World Health Organ. 1993;71:503-517.
36. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, Singh GM, Lin JK, Stevens GA, Riley LM, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Cholesterol). National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3·0 million participants. Lancet. 2011;377:578-586.
37. Marques-Vidal P, Ravasco P, Dias CM, Camilo ME. Trends of food intake in Portugal, 1987-1999: results from the National Health Surveys. Eur J Clin Nutr. 2006;60:1414-1422.
38. Chen Q, Marques-Vidal P. Trends in food availability in Portugal in 1966-2003: comparison with other Mediterranean countries. Eur J Nutr. 2007;46:418-427.
39. Teixeira IJ, Escoval A, Schiappa M. Lipid-lowering drugs: use and expenditure in Portugal (1995-2004). Rev Port Cardiol. 2007;26:475-493.